ImmunityBio, Inc. IBRX Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s stock-based comp?
- ImmunityBio, Inc. (IBRX) reported stock-based comp of $8.17M in Q1 2026.
- How has ImmunityBio, Inc.'s stock-based comp changed year-over-year?
- ImmunityBio, Inc.'s stock-based comp decreased by 14.3% year-over-year, from $9.54M to $8.17M.
- What is the long-term trend for ImmunityBio, Inc.'s stock-based comp?
- Over 4 years (2021 to 2025), ImmunityBio, Inc.'s stock-based comp has grown at a -10.4% compound annual growth rate (CAGR), from $57.18M to $36.81M.
- What does stock-based comp mean?
- The non-cash cost of equity-based compensation provided to employees.
- How do you interpret stock-based comp?
- High levels indicate significant dilution to shareholders, while low levels may suggest limited use of equity incentives.
- How does stock-based comp compare across companies?
- Standard across all industries; high-growth biotech firms typically have higher levels to attract specialized talent.